Remove Bioassay Remove Bioinformatics Remove Clinical Development Remove RNA
article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

Field also covered the capabilities and strategies that enable acceleration of Fc-fusion, Fab fragment and bispecific antibodies through pre-clinical development. It was presented by Xiaole Shirley Liu, PhD, CEO, GV20 Therapeutics, and titled: ‘AI-based target and antibody discovery from patient tumour profiles’.